Skip to Content
MilliporeSigma
  • Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.

Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.

Journal of pharmacological sciences (2014-06-27)
Hiroko Ono, Atsushi Nakamura, Tomoe Kanbara, Kazuhisa Minami, Shunji Shinohara, Gaku Sakaguchi, Toshiyuki Kanemasa
ABSTRACT

Although norepinephrine transporter (NET) inhibition has an additional effect on μ-opioid receptor (MOR)-mediated anti-nociception in inflammatory and neuropathic pain, its effect on cancer pain is not well characterized. We investigated the additional effect of NET inhibition on MOR activation using a mouse femur bone cancer (FBC) pain model by comparing the anti-nociceptive effect of the dual-acting opioids tramadol and tapentadol and the clinically used MOR-targeted opioids oxycodone and morphine. The anti-nociceptive effects of subcutaneously administered opioids were assessed using the von-Frey filament test. Oxycodone (1 - 10 mg/kg) and morphine (5 - 50 mg/kg) dose-dependently exhibited potent anti-nociceptive effects, whereas tramadol (10 - 56 mg/kg) and tapentadol (10 - 30 mg/kg) exhibited partial effects. Rota-rod analyses of tapentadol at a higher dose (> 30 mg/kg) showed a significant decrease in motor coordination, which was partially recovered by pretreatment with MOR or α(1)-adrenoceptor antagonists. The partial anti-nociceptive effect of tapentadol (30 mg/kg) was completely suppressed by a MOR antagonist, but not by α(1)- or α(2)-adrenoceptor antagonists, suggesting that neither α(1)-adrenoceptor- nor α(2)-adrenoceptor-mediated pathways are involved in anti-nociception in the FBC model. We conclude that addition of NET inhibition does not contribute to MOR-mediated anti-nociception in bone cancer pain.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
D-(+)-Glucose, SAJ special grade, ≥98.0%
Pricing and availability is not currently available.
Sigma-Aldrich
α-D-Glucose, anhydrous, 96%
Pricing and availability is not currently available.
Sigma-Aldrich
Glucose solution, BioUltra, for molecular biology, ~20% in H2O
Pricing and availability is not currently available.
Supelco
Oxaliplatin, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Supelco
Oxycodone hydrochloride, analytical standard
Pricing and availability is not currently available.
Sigma-Aldrich
D-(+)-Glucose solution, 100 g/L in H2O, sterile-filtered, BioXtra, suitable for cell culture
Pricing and availability is not currently available.
Sigma-Aldrich
D-(+)-Glucose solution, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Pricing and availability is not currently available.
Supelco
D-(+)-Glucose solution, 1 mg/mL in 0.1% benzoic acid, standard for enzymatic assay kits GAGO20, GAHK20, STA20, analytical standard
Pricing and availability is not currently available.
Sigma-Aldrich
Oxaliplatin, powder
Pricing and availability is not currently available.
Oxaliplatin, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
USP
Oxaliplatin, United States Pharmacopeia (USP) Reference Standard
Pricing and availability is not currently available.